Navigation Links
Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study
Date:12/7/2009

the Oralair(R) program as a whole, which remain extremely consistent. The development program, which focuses on the benefit to patients and fits squarely with current cost-containment trends, confirms the relevance of Stallergenes' strategic choices.

Our 2009 clinical news flow has been very dense and is not over yet. There are still more results to come and more analyses to be conducted. We will be delighted to present all these findings at an R&D day to be held at the start of 2010." says Albert Saporta, Chairman and CEO of Stallergenes.

ABOUT ORALAIR(R)

The Oralair(R) clinical development program has demonstrated the short-term efficacy of the product at an appropriate dose of 300 IR during the first season, through two clinical studies in adults and children (VO34.04 and VO52.06).

Through a pharmacodynamics study (V056.07), Stallergenes demonstrated that its immunotherapy tablet had an effect on symptoms from the very first month of treatment, without the use of rescue medication and irrespective of variable patient exposure to pollen.

The Oralair(R) development program, which has so far included over 1,800 patients, makes the level of clinical evidence for this treatment indisputable. This program, which was initiated in 2003 and is fully in line with EMEA guidelines issued in 2008, will help immunotherapy tablets achieve the same level of recognition as conventional pharmaceuticals.

From the outset, the Oralair(R) clinical development program has addressed the key issues involved in grass pollen immunotherapy:

    - It answers the unmet needs of patients suffering from severe
      rhino-conjunctivitis caused by grass pollen, inadequately controlled
      using symptomatic treatments,

    - It favors compliance and cost-containment, through its pre-
      and coseasonal protocol (the treatment is taken for four months prior
      to the pollen seaso
'/>"/>
SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. STALLERGENES: Oralair(R) Grasses Obtains a Pediatric MA(1) in Germany
2. Stallergenes: New Study VO 56 Highly Positive Results Conducted in an Allergen Challenge Chamber
3. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
4. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
5. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
6. Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
7. Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
8. Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony(TM) tCGM System in Patients with Type 1 and Type 2 Diabetes
9. Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results
10. Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
11. Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  Invivotek L.L.C., ... is pleased to announce that its animal research ... for the Assessment and Accreditation of Laboratory Animal ... of animals in science worldwide through voluntary accreditation ... for animal care and use in 38 countries. ...
(Date:7/14/2014)... , July 14, 2014  Today, ATS Labs, ... that it acquired the assets of MicroTest Labs, Inc. ... acquisition of MTL is the first step in the ... laboratory services platform to support the medical device and ... as Accuratus Lab Services , a name that ...
(Date:7/14/2014)... July 14, 2014  Medac Pharma, Inc., a ... of new molecules and improving the effectiveness of ... Drug Administration (FDA) has approved Rasuvo™, a subcutaneous ... for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis ... 10 dosage strengths, ranging from 7.5 mg to ...
Breaking Medicine Technology:Invivotek Awarded Full AAALAC Accreditation for Excellence in Laboratory Animal Care and Use 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8
(Date:7/14/2014)... The high demand in the current and ... of associations and regulatory bodies, and the population ... growth of the global rare earth metals market.The ... applications ranging from permanent magnets, catalysts, phosphors, glass ... America is the second-largest region in the world ...
(Date:7/14/2014)... A recent study published in the July 2014 issue ... Child and Adolescent Psychiatry confirms the validity of ... for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , In DSM-5, ... 7 in DSM-IV, has been raised to 12. As ... at 12, rather than an earlier age, to reflect ...
(Date:7/14/2014)... Philadelphia, PA, July 14, 2014 The inability to ... cognition often experienced by individuals diagnosed with schizophrenia, reports ... Biological Psychiatry . , Our brains are usually good ... to learn and filtering out the "noise" or thoughts ... be related in part to a problem with this ...
(Date:7/14/2014)... Chances are those dollars in your pocket have a ... notes in the U.S. do. Your cash also contains invisible ... it came out of the ATM. For more, watch this ... about the almighty dollar. The video is available at ... YouTube , and follow us on Twitter @ACSreactions ...
(Date:7/14/2014)... pathologist Lukas Kenner and his colleagues have developed a ... tissue sections and demonstrate the presence of specific biomarkers ... of the disease and leads to the most suitable ... study, "Two independent pathologists concur with each other only ... developed software offers, for the first time, the option ...
Breaking Medicine News(10 mins):Health News:North America Rare Earth Metals Market is Expected to Grow at a CAGR of 8% - New Report by MicroMarket Monitor 2Health News:North America Rare Earth Metals Market is Expected to Grow at a CAGR of 8% - New Report by MicroMarket Monitor 3Health News:North America Rare Earth Metals Market is Expected to Grow at a CAGR of 8% - New Report by MicroMarket Monitor 4Health News:'Noisy' memory in schizophrenia 2Health News:Scientists developed new technology for the diagnosis of cancer cells 2
... Two animal studies published in the journal Carcinogenesis show that ... physically active mice// that had a round the clock access ... other study found that exercise and a restricted diet had ... in the animals. ,The first study exposed mice ...
... new finding and revelation comes in the form of health ... the heart. ,The petition proposed as a model qualified health// ... (150 mL) of green tea as a source of catechins ... disease. FDA has determined that the evidence is supportive, but ...
... concern over the high maternal mortality rate in Madhya ... groups to help check the menace//. ,With 13,000 ... maternal mortality rate of the state is one of ... women's meet at the missionary-run Asha Niketan Welfare Centre ...
... which stated that doctors can give drugs to end the ... the upper house of British parliament//. The assisted dying bill ... stated that doctors can prescribe lethal drugs to patients who ... live. These drugs can be administered by the patients to ...
... have become so inadequate that students are becoming increasingly ... vital organs with each other. ,Senior doctors ... medical students are not being properly trained. ... properly trained in anatomy. According to them teaching hours ...
... percentages of undernourished children in the world, the situation ... report released Thursday//. ,"India's Integrated Child Development Services ... current malnutrition crisis," states the report "India's Undernourished Children: ... of underweight children in India is among the highest ...
Cached Medicine News:Health News:Green tea’s health claims questioned: FD 2Health News:Green tea’s health claims questioned: FD 3Health News:Malnutrition Crisis On Rise In India: World Bank 2
Measures up to 152 mm in 1 mm increments and 6 inches in 1/32 inch increments. Deeply etched graduations and dull finish....
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Endoscopes are also available in fully autoclavable models in 1.8, 2.7, 4.0. 5.0 and 10.0 mm diameters. Manufactured with precise swiss lenses. Built-in temperature measuring device to exactly determ...
Kleinert-Kutz Single Skin Hook, Large...
Medicine Products: